Overview

H-IVIG Treatment for Severe H1N1 2009

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Treatment with hyperimmune intravenous immunoglobulin (H-IVIG), derived from convalescent plasma from patients recovered from H1N1 2009 influenza A infection, for patients with severe H1N1 2009 infection will decrease mortality, reduce viral load, and shorten the length of stay in ICU and hospital.
Phase:
N/A
Details
Lead Sponsor:
The University of Hong Kong
Collaborators:
Caritas Medical Centre, Hong Kong
HK Red Cross Blood Transfusion Service, Hong Kong
Pamela Youde Nethersole Eastern Hospital
Queen Elizabeth Hospital, Hong Kong
Queen Mary Hospital, Hong Kong
Research Fund for the Control of Infectious Diseases, Hong Kong
Ruttonjee Hospital, Hong Kong
United Christian Hospital
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin